Dovilė Sinkevičiūtė
Dovilė Sinkevičiūtė publishes mostly in Rheumatology, Immunology and Immunology and Allergy, on topics such as Osteoarthritis Treatment and Mechanisms, Rheumatoid Arthritis Research and Therapies and Cell Adhesion Molecules Research.
- World rank
- #2,693,695 of 7,710,434 ranked researchers
- Rank in Denmark
- #20,046 of 43,819
- Works
- 35
- Citations
- 539
- Citations per work
- 15.4
What does Dovilė Sinkevičiūtė research?
Dovilė Sinkevičiūtė's work is mostly in Medicine (48%), Biochemistry, Genetics and Molecular Biology (14%), Immunology and Microbiology (10%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences1748.4%
- Medicine1748.4%
- Everything else1028.4%
- Life Sciences823.2%
- 1Rheumatology33% of their works
- 2Immunology10% of their works
- 3Immunology and Allergy10% of their works
- 4Molecular Biology8% of their works
- 5Oncology6% of their works
- 6Cell Biology5% of their works
Research topics
- Osteoarthritis Treatment and Mechanisms
- Rheumatoid Arthritis Research and Therapies
- Cell Adhesion Molecules Research
- Inflammatory mediators and NSAID effects
- Spondyloarthritis Studies and Treatments
- Protease and Inhibitor Mechanisms
- Psoriasis: Treatment and Pathogenesis
- Proteoglycans and glycosaminoglycans research
Which keywords describe Dovilė Sinkevičiūtė's research?
The keywords of their largest research topics: Inflammation, Cardiovascular Risk, Matrix Metalloproteinases, Angiogenesis, Cancer, Cartilage, Osteoarthritis and Biological Therapy.
- Hyaluronan
- TH17 Cells
- Cancer Progression
- Prostaglandins
- Cell Signaling
- Integrins
- Rheumatoid Arthritis
- Biological Therapy
- Cartilage
- Angiogenesis
- Cardiovascular Risk
- Inflammation
- Matrix Metalloproteinases
- Cancer
- Osteoarthritis
- Extracellular Matrix
- Cell Adhesion
- Ankylosing Spondylitis
- Cyclooxygenase-2 Inhibitors
- Spondyloarthritis
- IL-17
- Tissue Inhibitors of Metalloproteinases
- Proteoglycans
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 23 words, with their numbers
- Inflammation415 topics
- Cardiovascular Risk172 topics
- Matrix Metalloproteinases162 topics
- Angiogenesis143 topics
- Cancer142 topics
- Cartilage131 topic
- Osteoarthritis131 topic
- Biological Therapy121 topic
- Extracellular Matrix122 topics
- Rheumatoid Arthritis121 topic
- Cell Adhesion91 topic
- Integrins91 topic
- Ankylosing Spondylitis51 topic
- Cell Signaling52 topics
- Cyclooxygenase-2 Inhibitors51 topic
- Prostaglandins51 topic
- Spondyloarthritis51 topic
- Cancer Progression31 topic
- IL-1731 topic
- TH17 Cells31 topic
- Tissue Inhibitors of Metalloproteinases31 topic
- Hyaluronan21 topic
- Proteoglycans21 topic
Where does Dovilė Sinkevičiūtė work?
Dovilė Sinkevičiūtė's main affiliation in the publication record is Nordic Bioscience (Denmark), Denmark.
How many publications and citations does Dovilė Sinkevičiūtė have?
OpenAlex counts 35 works and 539 citations for Dovilė Sinkevičiūtė, an h-index of 10, ranking #2,693,695 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Dovilė Sinkevičiūtė. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.